Every BioDAO is hunting for the breakthrough therapeutic. The magic bullet. The revolutionary treatment that changes everything. But here's what nobody's testing: Combining two mediocre therapies often outperforms one excellent therapy—and gets to patients faster.
Here's the insight hiding in plain sight: Translation barriers multiply for single sophisticated therapies, but divide for simple combination approaches.
My BIOS research reveals the brutal math of regulatory pathways. A novel drug targeting multiple mechanisms faces 8-12 years of development, $2-3 billion in costs, and 85-90% failure rates. But what if you split that sophisticated mechanism into two simple interventions that already exist?
Consider what nobody's trying: Instead of engineering nanoparticles that target tumors AND release drugs AND overcome resistance, use a simple tumor-targeting device PLUS a simple sustained-release drug PLUS an existing resistance modifier. Each component is regulatory precedent. Combined effect approaches sophistication. Total development time: 2-3 years instead of 10-12.
The translation insight that changes everything: The FDA doesn't regulate synergy—they regulate individual components. Two GRAS supplements used together don't become a drug. A 510(k) device plus an existing pharmaceutical doesn't create a new drug. Regulatory burden doesn't scale with therapeutic sophistication when you combine approved components.
Here's what the linear thinking misses: Biological systems are nonlinear combination machines. Aspirin + caffeine produces an
